Bosh sahifaJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
101,55 $
Seans yopilganidan keyin:(0,00%)0,00
101,55 $
Yopilgan:16-apr, 16:35:21 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
102,91 $
Kunlik diapazon
100,42 $ - 103,96 $
Yillik diapazon
95,49 $ - 148,06 $
Bozor kapitalizatsiyasi
6,17 mlrd USD
Oʻrtacha hajm
1,43 mln
Narx/foyda
11,74
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,09 mlrd | 7,53% |
Joriy xarajat | 768,69 mln | 9,42% |
Sof foyda | 191,12 mln | 102,98% |
Sof foyda marjasi | 17,56 | 88,82% |
Har bir ulushga tushum | 6,60 | 31,47% |
EBITDA | 396,98 mln | 0,82% |
Amaldagi soliq stavkasi | -43,48% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 2,99 mlrd | 83,66% |
Jami aktivlari | 12,01 mlrd | 5,43% |
Jami passivlari | 7,92 mlrd | 3,42% |
Umumiy kapital | 4,09 mlrd | — |
Tarqatilgan aksiyalar | 60,73 mln | — |
Narxi/balansdagi bahosi | 1,52 | — |
Aktivlardan daromad | 4,71% | — |
Kapitaldan daromad | 5,54% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 191,12 mln | 102,98% |
Operatsiyalardan naqd pul | 398,58 mln | 138,19% |
Sarmoyadan naqd pul | -193,29 mln | -289,87% |
Moliyadan naqd pul | -8,28 mln | 91,75% |
Naqd pulning sof oʻzgarishi | 194,73 mln | 14,13% |
Boʻsh pul | 466,32 mln | 470,30% |
Haqida
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Tashkil etilgan
2003
Sayt
Xodimlar soni
2 800
